Arcellx, Inc. (ACLX) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Arcellx, Inc.'s filing signal turned positive.

Arcellx is a clinical-stage biotechnology company developing a novel class of immunotherapies powered by its proprietary D-Domain synthetic binding scaffold, designed to overcome limitations of traditional CAR-T therapies. Its lead program, anito-cel, a BCMA-targeting ddCAR, is under FDA review for relapsed or refractory multiple myeloma (rrMM), with a PDUFA date set for December 23, 2026. The company is also advancing its ARC-SparX platform, which offers dosable and controllable universal CAR-Ts, with programs targeting AML/MDS and other indications. Arcellx has a co-development and co-commercialization collaboration with Kite Pharma, a Gilead company, for anito-cel and other BCMA-targeting therapies. The company is also exploring anito-cel for autoimmune disorders, including generalized Myasthenia Gravis.

Revenue is primarily driven by collaboration revenue from its partnership with Kite Pharma, Inc., which includes upfront payments, milestone payments, and cost reimbursements related to the co-development and co-commercialization of anito-cel and other CAR-T cell therapies.